A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Inclusion Criteria:

• Has histologically confirmed diagnosis of RCC with clear cell component.

• Has received no prior systemic therapy for advanced ccRCC

• Male participants are abstinent from heterosexual intercourse or agree to usecontraception during and for at least 7 days after last dose of study interventionwith belzutifan and lenvatinib.

• Female participants are not pregnant or breastfeeding and are either not a woman ofchild-bearing potential (WOCBP) or use a contraceptive method that is highlyeffective or are abstinent from heterosexual intercourse during the interventionperiod and for at least 120 days after pembrolizumab or pembrolizumab/quavonlimab orfor at least 30 days after last dose of lenvatinib or belzutifan, whichever occurslast

• Has adequately controlled blood pressure with or without antihypertensivemedications

• Has adequate organ function.

• Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks prior to randomization/allocation

Exclusion Criteria:

• Has a known additional malignancy that is progressing or has required activetreatment within the past 3 years

• Has had major surgery, other than nephrectomy within 4 weeks prior to randomization

• Has known central nervous system (CNS) metastases and/or carcinomatous meningitis

• Has received prior radiotherapy within 2 weeks prior to first dose of studyintervention

• Has hypoxia or requires intermittent supplemental oxygen or requires chronicsupplemental oxygen

• Has clinically significant cardiac disease within 12 months from first dose of studyintervention

• Has a history of interstitial lung disease

• Has symptomatic pleural effusion; a participant who is clinically stable followingtreatment of this condition is eligible

• Has preexisting gastrointestinal or non-gastrointestinal fistula

• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapyor any other form of immunosuppressive therapy within 7 days prior to the first doseof study treatment

• Has a known psychiatric or substance abuse disorder that would interfere withrequirements of the study

• Has received a live or live-attenuated vaccine within 30 days before the first doseof study drug; killed vaccines are allowed

• Has an active autoimmune disease that has required systemic treatment in the past 2years

• Has a history of noninfectious pneumonitis that required steroids or has currentpneumonitis

• Has an active infection requiring systemic therapy

• Has a known history of human immunodeficiency virus (HIV) infection

• Has a known history of Hepatitis B

• Has radiographic evidence of intratumoral cavitation, encasement or invasion of amajor blood vessel

• Has clinically significant history of bleeding within 3 months prior torandomization

• Has had an allogenic tissue/solid organ transplant